tiprankstipranks
Advertisement
Advertisement
Inhibrx initiated with an Outperform at LifeSci Capital
PremiumThe FlyInhibrx initiated with an Outperform at LifeSci Capital
2M ago
Inhibrx price target raised to $300 from $150 at Stifel
Premium
The Fly
Inhibrx price target raised to $300 from $150 at Stifel
2M ago
Midday Fly By: Boeing, AT&T report Q1 beats
Premium
The Fly
Midday Fly By: Boeing, AT&T report Q1 beats
2M ago
Inhibrx Biosciences Highlights Promising Ozekibart Colorectal Cancer Data
PremiumCompany AnnouncementsInhibrx Biosciences Highlights Promising Ozekibart Colorectal Cancer Data
2M ago
Inhibrx reports interim data from its Phase 1/2 study evaluating ozekibart
Premium
The Fly
Inhibrx reports interim data from its Phase 1/2 study evaluating ozekibart
2M ago
Coinbase downgraded, Deere upgraded: Wall Street’s top analyst calls
Premium
The Fly
Coinbase downgraded, Deere upgraded: Wall Street’s top analyst calls
2M ago
Inhibrx provides update on INBRX-106 Phase 2/3 clinical trial
PremiumThe FlyInhibrx provides update on INBRX-106 Phase 2/3 clinical trial
6M ago
Premium
Company Announcements
Inhibrx Biosciences Reports Promising Q3 2025 Results
7M ago
Inhibrx options imply 7.3% move in share price post-earnings
Premium
The Fly
Inhibrx options imply 7.3% move in share price post-earnings
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100